A Study of DS3610a in Participants With Advanced Solid Tumor

Part of paid clinical trials in Milwaukee, Wisconsin.

Sponsor
Daiichi Sankyo
Study ID
NCT07159126
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Metastatic Solid Tumors
  • Solid Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • DS3610a — DRUG
    Participants will receive DS3610a at the target dose. Treatment will continue until radiographic disease progression, as determined by the investigator, or until another reason for discontinuation of trial intervention occurs.

Study Details

This study is designed to assess the safety, tolerability, and efficacy of DS3610a, given as a single agent to participants with advanced or metastatic solid tumors.

Key Dates

First listed
Sep 8, 2025
Start date
Oct 9, 2025
Status verified
Sep 2026
Primary completion
Sep 1, 2028
Completion
Feb 1, 2031

Study Design

Enrollment
70 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: DS3610a at Escalating Doses
    Participants will receive DS3610a at escalating doses. The RDE will be determined using data collected from this arm.

Primary Outcome Measure

Dose Limiting Toxicities [ Time Frame: From first dose, up to approximately 24 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Froedtert Hospital and the Medical College of WisconsinMilwaukeeWisconsin53226-

Find similar trials in Milwaukee, WI

By research site
Froedtert Hospital and the Medical College of Wisconsin· Milwaukee, WI

Related Studies